417 related articles for article (PubMed ID: 32853673)
1. Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants.
Catteau L; Dauby N; Montourcy M; Bottieau E; Hautekiet J; Goetghebeur E; van Ierssel S; Duysburgh E; Van Oyen H; Wyndham-Thomas C; Van Beckhoven D;
Int J Antimicrob Agents; 2020 Oct; 56(4):106144. PubMed ID: 32853673
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial.
Sekhavati E; Jafari F; SeyedAlinaghi S; Jamalimoghadamsiahkali S; Sadr S; Tabarestani M; Pirhayati M; Zendehdel A; Manafi N; Hajiabdolbaghi M; Ahmadinejad Z; Kouchak HE; Jafari S; Khalili H; Salehi M; Seifi A; Golestan FS; Ghiasvand F
Int J Antimicrob Agents; 2020 Oct; 56(4):106143. PubMed ID: 32853672
[TBL] [Abstract][Full Text] [Related]
3. Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time.
Davido B; Boussaid G; Vaugier I; Lansaman T; Bouchand F; Lawrence C; Alvarez JC; Moine P; Perronne V; Barbot F; Saleh-Mghir A; Perronne C; Annane D; De Truchis P;
Int J Antimicrob Agents; 2020 Oct; 56(4):106129. PubMed ID: 32755653
[TBL] [Abstract][Full Text] [Related]
4. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
[TBL] [Abstract][Full Text] [Related]
5. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.
Ip A; Berry DA; Hansen E; Goy AH; Pecora AL; Sinclaire BA; Bednarz U; Marafelias M; Berry SM; Berry NS; Mathura S; Sawczuk IS; Biran N; Go RC; Sperber S; Piwoz JA; Balani B; Cicogna C; Sebti R; Zuckerman J; Rose KM; Tank L; Jacobs LG; Korcak J; Timmapuri SL; Underwood JP; Sugalski G; Barsky C; Varga DW; Asif A; Landolfi JC; Goldberg SL
PLoS One; 2020; 15(8):e0237693. PubMed ID: 32790733
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review.
Roomi S; Ullah W; Ahmed F; Farooq S; Sadiq U; Chohan A; Jafar M; Saddique M; Khanal S; Watson R; Boigon M
J Med Internet Res; 2020 Sep; 22(9):e21758. PubMed ID: 32784192
[TBL] [Abstract][Full Text] [Related]
7. RETRACTED: Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study.
Abd-Elsalam S; Esmail ES; Khalaf M; Abdo EF; Medhat MA; Abd El Ghafar MS; Ahmed OA; Soliman S; Serangawy GN; Alboraie M
Am J Trop Med Hyg; 2020 Oct; 103(4):1635-1639. PubMed ID: 32828135
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis.
Lagier JC; Million M; Gautret P; Colson P; Cortaredona S; Giraud-Gatineau A; Honoré S; Gaubert JY; Fournier PE; Tissot-Dupont H; Chabrière E; Stein A; Deharo JC; Fenollar F; Rolain JM; Obadia Y; Jacquier A; La Scola B; Brouqui P; Drancourt M; Parola P; Raoult D;
Travel Med Infect Dis; 2020; 36():101791. PubMed ID: 32593867
[TBL] [Abstract][Full Text] [Related]
9. Effect of chloroquine and hydroxychloroquine on COVID-19 virological outcomes: An updated meta-analysis.
Das RR; Behera B; Mishra B; Naik SS
Indian J Med Microbiol; 2020; 38(3 & 4):265-272. PubMed ID: 33154234
[TBL] [Abstract][Full Text] [Related]
10. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.
Padilla S; Telenti G; Guillén L; García JA; García-Abellán J; Ding C; Mora A; García-Pachón E; Gutiérrez F; Masiá M;
Int J Antimicrob Agents; 2020 Oct; 56(4):106142. PubMed ID: 32853675
[TBL] [Abstract][Full Text] [Related]
12. Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study.
Kalligeros M; Shehadeh F; Atalla E; Mylona EK; Aung S; Pandita A; Larkin J; Sanchez M; Touzard-Romo F; Brotherton A; Shah R; Cunha CB; Mylonakis E
J Glob Antimicrob Resist; 2020 Sep; 22():842-844. PubMed ID: 32763357
[TBL] [Abstract][Full Text] [Related]
13. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.
Rosenberg ES; Dufort EM; Udo T; Wilberschied LA; Kumar J; Tesoriero J; Weinberg P; Kirkwood J; Muse A; DeHovitz J; Blog DS; Hutton B; Holtgrave DR; Zucker HA
JAMA; 2020 Jun; 323(24):2493-2502. PubMed ID: 32392282
[TBL] [Abstract][Full Text] [Related]
14. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis.
Sarma P; Kaur H; Kumar H; Mahendru D; Avti P; Bhattacharyya A; Prajapat M; Shekhar N; Kumar S; Singh R; Singh A; Dhibar DP; Prakash A; Medhi B
J Med Virol; 2020 Jul; 92(7):776-785. PubMed ID: 32297988
[TBL] [Abstract][Full Text] [Related]
15. Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings.
Abena PM; Decloedt EH; Bottieau E; Suleman F; Adejumo P; Sam-Agudu NA; Muyembe TamFum JJ; Seydi M; Eholie SP; Mills EJ; Kallay O; Zumla A; Nachega JB
Am J Trop Med Hyg; 2020 Jun; 102(6):1184-1188. PubMed ID: 32323646
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
17. Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection.
Giaime P; Guenoun M; Pedinielli N; Narbonne H; Bergounioux JP; Solas C; Guilhaumou R; Sampol J; Ollier J; Sichez H; Serveaux M; Brunner F; Bataille S
Nephrol Dial Transplant; 2020 Aug; 35(8):1346-1353. PubMed ID: 32844224
[TBL] [Abstract][Full Text] [Related]
18. The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis.
Ayele Mega T; Feyissa TM; Dessalegn Bosho D; Kumela Goro K; Zeleke Negera G
Can Respir J; 2020; 2020():4312519. PubMed ID: 33082891
[TBL] [Abstract][Full Text] [Related]
19. A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality.
Fernández-Cruz A; Ruiz-Antorán B; Muñoz-Gómez A; Sancho-López A; Mills-Sánchez P; Centeno-Soto GA; Blanco-Alonso S; Javaloyes-Garachana L; Galán-Gómez A; Valencia-Alijo Á; Gómez-Irusta J; Payares-Herrera C; Morrás-Torre I; Sánchez-Chica E; Delgado-Téllez-de-Cepeda L; Callejas-Díaz A; Ramos-Martínez A; Múñez-Rubio E; Avendaño-Solá C
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32571831
[TBL] [Abstract][Full Text] [Related]
20. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32641296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
